- NASDAQ: APM ended Tuesday's session with a surge of 90% after hitting even higher levels.
- Shares then collapsed back below $3, completing a pump-and-dump move.
- Aptorum Group launched a new unit focused on an infectious disease liquid biopsy unit.
- Venturing into a new field involving the coronavirus implies strong growth for the low-valued company.
When a stock trades at rock-bottom levels, a small spark is all that is needed to trigger a surge. Aptorum Group Ltd nearly quadrupled in value in Tuesday's intense session, closing at $4.76 after already hitting a high of $14.23. Shares then collapsed back below $3 on a Wednesday session dominated by bears, taking the price back nearly to Monday's levels. On Thursday, trading action was quiet, with NASDAQ:APM closing at $2.89 after staying the whole session between $2.7 and $3.1.
After the recent leap and plunge, NASDAQ: APM's market capitalization is only $87.82 million. Can it rise?
APM Stock News
Aptorum jumped after announcing the launch of Aptorum Innovations, a subsidiary focused on infectious disease liquid biopsy diagnostics. When speaking of diseases that spread rapidly, SARS-Cov-2 – the virus behind COVID-19 – immediately comes to mind.
Indeed, Aptorum has in-licensed exclusive rights to develop novel molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology with a Singapore-based company called Accelerate Technologies PTE Ltd. The fir is the commercialization arm of the city-state's Agency for Science, Technology, and Research.
The collaboration with a firm backed by Singapore – a country that successfully battled the coronavirus, is inspiring investors.
While several COVID-19 vaccines are at a late stage, there is still room for those specializing in rapid identification of this coronavirus and potentially new ones that could appear in recent years. It is essential to note that the full mitigation of the original SARS disease from 2002-2003 was never fully achieved.
Broader markets are focused on the chaotic presidential debate – which veered away from the virus – yet its prominence is still critical for investors.
See Presidential Debate: Stocks set to suffer on Trump's refusal to accept the results
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: A deeper retracement looks likely
Finally, AUD/USD regain some composure and partially recouped ground lost in the previous day helped by the increasing selling bias hurting the US Dollar ahead of the publication of the key US labour market report on Friday
EUR/USD gears up for a probable move to 1.0600
EUR/USD advanced for the third consecutive day on Thursday, supported by persistent selling pressure on the Greenback and cautious sentiment ahead of the US Nonfarm Payrolls report on Friday.
Gold tumbles as US yields jump as traders await US Nonfarm Payrolls
Gold price retreats on Thursday as investors digested the latest US jobless claims data, ahead of the release of November’s Nonfarm Payrolls figures. A jump in US Treasury bond yields weighed on the yellow metal, which dropped 0.85%, trading at $2,626.
Gamestop, GME meme coin surge following Roaring Kitty return
Gamestop-based meme coins rose more than 40% on Thursday after popular trader, Keith Gill, stirred excitement in the meme coin sector with a post featuring a Time Magazine picture on social media platform X.
GBP/USD loses momentum and revisits 1.2750
Following an initial move to peaks around 1.2770, GBP/USD now surrenders part of that advance and slips back to the mid-1.2700s amid the steady downtrend in the Greenback.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.